Please try another search
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Name | Age | Since | Title |
---|---|---|---|
Jeremy Bender | 51 | 2020 | CEO, President & Director |
Garry A. Nicholson | 68 | 2022 | Chairman of the Board & Lead Independent Director |
Natalie C. Holles | 50 | 2021 | Independent Director |
John A. Josey | 62 | 2020 | Independent Director |
Sona Saira Ramasastry | 47 | 2021 | Independent Director |
Michael Gladstone | 36 | 2019 | Independent Director |
Daniel J. Becker | 48 | 2019 | Independent Director |
Daniel Curran | 55 | - | Board Observer |
Scott Garland | 54 | 2021 | Independent Director |
David S. Grayzel | 55 | - | Board Observer |
Habib Joseph Dable | 55 | 2024 | Independent Director |
William J. Grossman | 53 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review